CTX biochemical marker of bone metabolism. is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study

Implant Dentistry

Volumn 19, Issue 1, 2010, Pages 29-38

  Lee, Cameron Y S ^a   Suzuki, Jon B ^b  

^a Oral   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

BP associated osteonecrosis; CTX test; Risk; Validity

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

AGED; ARTICLE; BLOOD; BONE NECROSIS; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; JAW DISEASE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL SURGERY; PHYSIOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; PEPTIDES; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 77049083632     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/ID.0b013e3181cec8bc     Document Type: Article

References (26)

1. Melo M, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111-113.
2. Engroff S, Kim D. Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg. 2007;65: 2374-2385.
3. Fleisher KE, Doty S, Kottal S, et al. Tetracycline-guided debridement and cone bam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: A technical note. J Oral Maxillofac Surg. 2008;66:2646-2653.
4. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk-factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg. 2007;65: 2397-2410.
5. Assael LA. Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: Paths toward minimizing surgical risk? [Editorial]. J Oral Maxillofac Surg. 2007;65:2395-2396.
6. Schwartz HC. Serum CTX testing [Letter to the editor]. J Oral Maxillofac Surg. 2008;66:1319-1320.
7. Khosla S, Burr D, Cawley J, et al. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment [Letter to the editor]. J Oral Maxillofac Surg. 2008; 66:1320-1321.
8. Zak M, Spina AM, Spinazze RP, et al. Bisphosphonates and the dental patient: Part 2. Compend Contin Educ Dent. 2007;28:510-516.
9. Koka S. Osteonecrosis of the jaw and biomarkers: What do we tell our patients? [Editorial]. Int J Oral Maxillofac Implants. 2008;23:179-180.
10. Orwoll ES, Bell NH, Nanes MS, et al. Collagen N-telopeptide excretion in men: The effects of age and intrasubject variability. J Clin Endoclinol Metab. 1998; 83:3930-3935.
11. Greenspan SL, Rosen HN, Parker RA. Early changes in serum ntelopeptide and c-telopeptide crosslinked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-3540.
12. Garnero P, Borel O, Delmas P. Evaluation of a fully automated serum assay for c-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47:694-702.
13. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the serum crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 1998;44:2290-2300.
14. Rosenquist C, Fledelius C, Christgau S, et al. Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998;44:2281-2289.
15. Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996; 59:328-333.
16. Advisory Task Force on Bisphoshonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.
17. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67:2-12.
18. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. An institutional inquiry. J Am Dent Assoc. 2009;140:61-66.
19. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
20. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.
21. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100-103.
22. Christgau S, Bitsch-Jensen O, Bjarnason NH, et al. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 2000;26:505-511.
23. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 1999;24:237-244.
24. Wang HL, Weber D, McCauley LK, et al. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol. 2007;78:584-594.
25. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 2008;66:625-631.
26. Glick M. Closing in on the puzzle of ONJ [Editorial]. J Am Dent Assoc. 2008; 139:12-15.